Drug Trial Radar · NCT01491815
Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
Last checked: Nov 19, 2026Latest source record: Jul 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
812
Actual
Start
Dec 14, 2012
Primary completion
Jul 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Karolinska InstitutetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international (Sweden, Finland, Norway, Denmark, Iceland and the Netherlands) trial designed to compare the safety and efficacy of active conventional therapy (ACT) and three biologic treatments in subjects with early rheumatoid arthritis (RA). The global aim of this study is to assess and compare 1. the proportion of subjects who achieve remission with ACT versus three different biologic therapies (Certolizumab-pegol, Abatacept or Tocilizumab) 2. two alternative de-escalation strategies in patients who respond to first-line therapy.
Conditions
- Rheumatoid Arthritis
Interventions
Non-biological DMARD'sDrug
Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
CimziaBiological
Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
OrenciaBiological
Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
RoActemraBiological
Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients in remission at week 24 from baseline according to CDAITime frame: 24 weeks from BL
- The proportion of patients in remission at week 24 after dose-reduction according to CDAITime frame: 24 weeks after dose-reduction
- The radiographic progression of total Sharp van der Heijde score after 48 weeks from baselineTime frame: 48 weeks from BL
Locations
30 sites in 6 countries. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Odense University Hospital
Odense, Denmark
Silkeborg University Clinic
Silkeborg, Denmark
University Hospital of Southern Denmark
Sønderborg, Denmark
Svendborg Hospital OUH
Svendborg, Denmark
Helsinki University Central Hospital
Helsinki, Finland
Central Finland Central Hospital
Jyväskylä, Finland
Kuopio University Hospital
Kuopio, Finland
Tampere University Hospital
Tampere, Finland
Landspitali University Hospital
Reykjavik, Iceland
Reade
Amsterdam, Netherlands
Ålesund Hospital
Ålesund, Norway
Haukeland University Hospital
Bergen, Norway
Diakonhjemmet Hospital
Oslo, Norway
University Hospital of North Norway
Tromsø, Norway
St. Olav's Hospital
Trondheim, Norway
Falu Hospital
Falun, Sweden
Sahlgrenska University Hospital
Gothenburg, Sweden
The Karolinska University Hospital
Huddinge, Sweden
Linköping University Hospital
Linköping, Sweden
Skåne University Hospital
Lund, Sweden
Skåne University Hospital
Malmö, Sweden
Örebro University Hospital
Örebro, Sweden
The Karolinska University Hospital
Solna, Sweden
Academic Specialist Center
Stockholm, Sweden
The Karolinska Institutet
Stockholm, Sweden
Uppsala University Hospital
Uppsala, Sweden
Västmanlands Hospital
Västerås, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.